Ask AI
ProCE Banner Activity

Think Tank on Emerging HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Clinical Thought

Read our thoughts on incorporating emerging anti-HER2 ADCs into the management of genitourinary, gastrointestinal, and gynecologic malignancies, including insights on HER2 testing, the latest clinical data, and expert management of adverse events.

Released: March 22, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Kathleen N. Moore, MD, MS, FASCO

Deputy Director and Director of Phase 1
Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska
ASCO BOD
GOG F BOD

Kathleen N. Moore, MD, MS, FASCO: consultant/advisor/speaker: Aadi, AbbVie, AstraZeneca, BeOne, BioNTech, Corcept, Daiichi Sankyo, Duality, Eisai, GSK, Immunogen, Iovance, Janssen, Merck, Regeneron, Schrödinger, Takeda, Verastem, Whitehawk, Zentalis, Zymeworks.

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, FASCO: consultant/advisor/speaker: Astellas, AstraZeneca, Eisai, EMD Serono, IMV, Merck, Pfizer, Seagen/Esquared, Seattle Genetics, Synthekine.

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology Program
UCLA School of Medicine
Los Angeles, California

Zev A. Wainberg, MD: consultant/advisor/speaker: Alligator, Amgen, Arcus, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Janssen, Lilly, Merck, Novartis, Pfizer, Rev Med.